Coherus BioSciences Price to Book Ratio 2013-2021 | CHRS

Historical price to book ratio values for Coherus BioSciences (CHRS) over the last 10 years. The current price to book ratio for Coherus BioSciences as of October 26, 2021 is 8.03.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Coherus BioSciences Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-27 16.07 7.87
2021-06-30 13.83 $2.04 6.77
2021-03-31 14.61 $1.75 8.37
2020-12-31 17.38 $3.87 4.49
2020-09-30 18.34 $3.55 5.17
2020-06-30 17.86 $2.99 5.97
2020-03-31 16.22 $2.22 7.31
2019-12-31 18.01 $1.50 12.04
2019-09-30 20.26 $0.80 25.35
2019-06-30 22.10 $-0.06 -386.36
2019-03-31 13.64 $-0.56 -24.55
2018-12-31 9.05 $-0.57 -16.02
2018-09-30 16.50 $0.18 90.56
2018-06-30 14.00 $0.91 15.36
2018-03-31 11.05 $-0.05 -218.81
2017-12-31 8.80 $0.51 17.24
2017-09-30 13.35 $0.95 14.09
2017-06-30 14.35 $0.60 23.88
2017-03-31 21.15 $1.50 14.10
2016-12-31 28.15 $0.42 66.63
2016-09-30 26.78 $0.73 36.85
2016-06-30 16.89 $-1.43 -11.83
2016-03-31 21.23 $-1.71 -12.43
2015-12-31 22.96 $-0.18 -129.28
2015-09-30 20.04 $1.03 19.42
2015-06-30 28.90 $2.52 11.46
2015-03-31 30.58 $1.13 27.12
2014-12-31 16.32 $2.01 8.13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.254B $0.476B
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86